

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



国药集团
SINOPHARM

CHINA TRADITIONAL CHINESE MEDICINE HOLDINGS CO. LIMITED
中國中藥控股有限公司

(Incorporated in Hong Kong with limited liability)
(Stock Code: 570)

RETIREMENT OF AUDITOR

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of China Traditional Chinese Medicine Holdings Co. Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.51(4) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

China National Pharmaceutical Group Co., Ltd. (“**CNPGC**”), the ultimate controlling shareholder of the Company, is a central state-owned enterprise regulated by the State-owned Assets Supervision and administration Commission of the State Council of the People’s Republic of China (“**SASAC**”). Under the relevant requirements of the Ministry of Finance of the People’s Republic of China and SASAC, there are certain limits to the number of years for which an accounting firm may continuously undertake financial auditing work in respect of a central state-owned enterprise and its subsidiaries.

As the Company is a subsidiary of CNPGC and subject to the aforementioned rotation requirements, accordingly, Ernst & Young (“**E&Y**”) will retire as the auditor of the Company at the conclusion of the forthcoming annual general meeting of the Company (the “**AGM**”) upon the expiration of its current term of office and will not be re-appointed as the auditor of the Company at the AGM.

E&Y has confirmed in writing that there are no matters in connection with its retirement as the auditor of the Company that should be brought to the attention of the shareholders of the Company (the “**Shareholders**”). The Board has confirmed that, there is no disagreement or unsolved matters between the Company and E&Y, and there are no matters in relation to the retirement of E&Y that need to be brought to the attention of the Shareholders.

As at the date of this announcement, E&Y has not commenced any audit work on the consolidated financial statements of the Group for the year ending 31 December 2025. Accordingly, the Board considers that the retirement of E&Y as the auditor of the Company will not have any significant impact on the annual audit and release of the annual results of the Group for the year ending 31 December 2025.

The Board would like to take this opportunity to express its sincere gratitude to E&Y for its professional services and support provided to the Company during the past years.

The Company is in the process of identifying a suitable replacement to fill the casual vacancy resulting from the retirement of E&Y. Further announcement in relation to the appointment of new auditor will be made by the Company as and when appropriate.

By Order of the Board
China Traditional Chinese Medicine Holdings Co. Limited
YANG Jun
Chairman

Hong Kong, 29 May 2025

As at the date of this announcement, the Board comprises eleven Directors, of which Mr. YANG Jun and Mr. LI Hongjian are executive Directors; Mr. LIU Haijian, Mr. LI Xiangrong, Mr. ZU Jing, Ms. XU Jinghui and Mr. HUANG Hao are non-executive Directors; and Mr. XIE Rong, Mr. YU Tze Shan Hailson, Mr. QIN Ling and Mr. LI Weidong are independent non-executive Directors.